BlinkLab

September 2024 Quarterly Activities Report and Appendix 4C

Advancing global neurodiagnostics with strategic partnerships and regulatory milestones on a pathway to commercialisation

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”) an innovative digital healthcare company leveraging smartphones, computer vision, Al and machine learning to diagnose neurodevelopmental conditions, is pleased to release its Appendix 4C and Quarterly Activity Report for the period ended 30 September 2024. During the quarter the Company made significant progress towards the launch of its upcoming FDA registration study, which is on-track to commence before the calendar year end.


Highlights

  • FDA registration study on track to commence this calendar year.
  • Strategic partnerships signed with leading outpatient mental healthcare providers in Europe, for Autism and ADM/
  • Several clinical studies in Autism, ADI-D), Frontotemporal Dementia, Functional Neurological Disorders, Spinocerebellar Ataxia, with top European and US institutions are ongoing and results are expected next calendar year.
  • Commenced regulatory work towards obtaining ISO/CE mark certifications in Europe to support future commercial launch.
  • As at 30 September 2024, the Company had a cash balance of A$5.4 million following the $7 million IPO in April.
BlinkLab was also pleased to announce several new strategic partnerships which confirmed the continuing adoption of BlinkLab's products with world-renowned research institutions. The rapid progress in making the Company's cutting-edge technology available to healthcare practitioners, families and caregivers is exciting for the BlinkLab team.

Strong progress towards initiation of FDA clinical study later this year for "BlinkLab Dx 1" We are pleased to report that, after a competitive selection process, BlinkLab are in the final stages of appointing a world-recognised Clinical Research Organisation ("CRO"), with a track record of obtaining regulatory approvals for digital healthcare and medical devices, to co­ordinate our upcoming FDA registration trial.

Throughout the quarter, the Company continued work on finalising the study protocol, engaging with FDA as well as reaching out and interacting with future US based clinical sites that will be conducting the registrational studies. Before the end of CY 2024, we expect to announce the outcomes of this work. We are excited about the progress that our regulatory and development team is making to start the FDA study that we believe will be the largest smartphone based clinical study in the world, in the field of autism diagnostics.

Strategic Partnerships with large European Mental Healthcare Providers

During the past quarter, we announced two major clinical and future commercialisation partnerships with large European mental healthcare providers. Together with Mental Care Group and INTER-PSY, BlinkLab has launched companion clinical studies in ADHD and autism, evaluating whether the Company's technology can enhance diagnostic accuracy and efficiency in clinical settings, with a future commitment to commercialise our products with these partners in Europe upon successful outcomes. With a national network of over 200 clinical centres serving over 100,000 patients annually, these partnerships are a huge endorsement of the BlinkLab smartphone-based tests and the potential to grow successfully outside the US.

Ongoing Work Towards Obtaining European Certifications of BlinkLab Product

As the Company continues to support the activities for the launch of FDA registrational study, the BlinkLab team has also initiated work towards obtaining applicable regulatory clearances to be able to launch the product outside the US.

Under the EU Medical Device Regulation (MDR) 2017/745, the BlinkLab diagnostic platform is classified as a class Ila medical device and will require CE marking of conformity before the device can be launched on the market. The conformity work will include implementation of quality management systems (IS013485 certification), usability engineering, labelling, adherence to general data protection regulation (GDPR), developing appropriate post-market surveillance plan and other activities. This work commenced during the prior quarter, and the Company will be providing ongoing updates as it moves forward towards EU certification and future launch in markets outside the US.

Ongoing Clinical Studies in Other Indications with World Leading Research Organisations

Since listing on the Australian Securities Exchange in April this year, BlinkLab has announced multiple clinical research collaborations with several world-renowned research institutions to conduct studies in mental and developmental conditions outside of autism and ADHD.

The data collected from these studies is fundamental to the Company's diagnostic platform and machine learning models, as distinguishing autism and ADHD from other psychiatric disorders in the real world is difficult due to their multidimensional phenotypes and significant overlap of symptoms and characteristics.

At BlinkLab we are trying to fundamentally change the diagnostic approach by collecting digital phenotype data from the broadest possible range of neurodevelopmental and neurodegenerative conditions. By training the model on large data sets from various diseases, we significantly improve future predictive performance of the BlinkLab application in real-world scenarios.


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BB1:AU
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BlinkLab Limited

BlinkLab Limited


Keep reading...Show less

Revolutionising Mental Health Care Through Mobile Solutions

Logos of OpenAI and Microsoft with "Tech 5" on an abstract tech-themed background.

Tech 5: OpenAI/Microsoft Talks Get Tense, SoftBank Floats Arizona Robotics Hub

This week, Microsoft (NASDAQ:MSFT) and OpenAI's once tight alliance showed signs of strain, while Meta Platforms (NASDAQ:META) continued to source artificial intelligence (AI) talent from rival companies.

Meanwhile, SoftBank's (TSE:9434) CEO is considering a new chip and robotics venture in Arizona, and Google (NASDAQ:GOOGL) is looking to bring AI solutions to American cities.

Read on to dive deeper into this week's top tech stories.

Keep reading...Show less
Hand touching AI hologram with tech circuit pattern.

Tech 5: Meta Plans Multibillion AI Bet, Apple Reveals iOS 26 at WWDC 2025

This week saw a flurry of activity in the tech world, from Apple's (NASDAQ:AAPL) new product announcements to Amazon's (NASDAQ:AMZN) massive infrastructure investment in Pennsylvania.

Meanwhile, NVIDIA's (NASDAQ:NVDA) European expansion and its role as an artificial intelligence (AI) powerhouse were all but cemented after a series of announcements at the Paris VivaTech Conference, and Mark Zuckerberg's Meta Platforms (NASDAQ:META) made big moves in the AI startup space.

Read on to dive deeper into this week's top tech stories.

Keep reading...Show less
3D model of an intricate oil reservoir.

Why 3D Visualisation is a Game Changer for Resource Asset Management

Forget spreadsheets and static blueprints. The future of resource asset management is unfolding in three dimensions, and smart money is starting to take notice.

3D visualisation is no longer a niche tool; it's rapidly becoming the indispensable core of how resource companies — such as mining, oil and gas and utilities — are tackling their most pressing challenges, from optimising daily operations to achieving critical environmental, social and governance objectives. For investors, this isn't just a technological upgrade; it's a paradigm shift with significant implications for portfolio performance.

Keep reading...Show less
Digital security concept with shield icon and abstract network design.

Tech 5: CoreWeave and Applied Digital Strike Deal, Startup Anduril Raises US$2.5 Billion

This week’s developments across the tech sector underscored the deepening connection between advanced computing, capital flows and geopolitical dynamics.

Applied Digital (NASDAQ:APLD) secured a landmark agreement with CoreWeave (NASDAQ:CRWV), while Broadcom’s (NASDAQ:AVGO) newest high-performance chip hit the market. Meanwhile, Canada’s Cohere is reportedly seeking fresh funding as it builds momentum in the enterprise artificial intelligence (AI) space.

In the defense sector, Anduril Industries secured a new round of funding, and elsewhere geopolitical tensions made their mark on Apple’s (NASDAQ:APPL) AI rollout in China.

Keep reading...Show less
Vancouver Convention Center and skyline.

Web Summit 2025: AI Innovation, Investment Shifts and Global Tech Alliances Take Center Stage

The Vancouver edition of Web Summit took place last week, bringing 15,727 attendees from 117 countries together, including 159 partners, 681 investors and 50 trade delegations.

A record-breaking 1,108 startups across a range of tech-touching industries exhibited, showcasing their products, services and ideas, from groundbreaking biotech advancements to revolutionary sustainable energy solutions.

Artificial intelligence (AI) was a prominent feature across all these innovations, underscoring the rapid pace of technological advancement and its pervasive influence across all aspects of modern life.

Keep reading...Show less
US flag on a microchip with red, white and blue circuit lines on a black background.

Trump Admin Strips "Safety" from AI Oversight Institute in Move to Rebrand

The Trump administration announced a rebrand of the US Artificial Intelligence (AI) Safety Institute, stripping the word “safety” from the organization's title and mission.

The institute, once tasked with developing standards to ensure AI model transparency, robustness and reliability, will now be known as the Center for AI Standards and Innovation (CAISI). According to the announcement, its focus will be on enhancing US competitiveness and guarding against foreign threats, not constraining the industry with regulations.

The decision, announced on Tuesday (June 3) by US Secretary of Commerce Howard Lutnick, marks a sharp departure from the Biden-era posture on AI governance.

Keep reading...Show less
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×